Tangent Medical Showcases the NovaCath(TM) Integrated IV Catheter System at National Event Committed to Healthcare Innovation

Tangent Medical Showcases the NovaCath(TM) Integrated IV Catheter System at National Event Committed to Healthcare Innovation

June 12, 2013

Tangent Medical (www.tangentmedical.com), an innovator in IV therapy products and creator of the NovaCath™ Integrated IV Catheter System, was one of 14 medical innovations featured at the Premier healthcare alliance's 2013 Breakthrough Conference and Exhibition on June 11th in San Antonio.

BG Medicine Welcomes Inclusion of Galectin-3 as Biomarker of Myocardial Fibrosis in 2013 ACCF/AHA Guideline for Management of Heart Failure

BG Medicine Welcomes Inclusion of Galectin-3 as Biomarker of Myocardial Fibrosis in 2013 ACCF/AHA Guideline for Management of Heart Failure

June 12, 2013

Galectin-3 Cited as an Emerging Biomarker for Risk Prediction in Patients With Heart Failure

Agios Pharmaceuticals files for IPO of up to $86 million

Agios Pharmaceuticals files for IPO of up to $86 million

June 11, 2013

(Reuters) - Biopharmaceutical company Agios Pharmaceuticals Inc filed with U.S. regulators on Monday to raise up to $86 million in an initial public offering of common stock.

The Cambridge, Massachusetts-based company told the U.S. Securities and Exchange Commission in a preliminary prospectus that JP Morgan and Goldman Sachs & Co are lead underwriters in the IPO.

Lallemand Biofuels & Distilled Spirits and Mascoma Announce Introduction of Next Generation Bioengineered Yeast

Lallemand Biofuels & Distilled Spirits and Mascoma Announce Introduction of Next Generation Bioengineered Yeast

June 10, 2013

— Lallemand Biofuels & Distilled Spirits, a global provider of fermentation ingredients to the fuel ethanol industry, and Mascoma Corporation, a renewable fuels company, today announced the introduction of their next generation advanced yeast product, TransFerm® Yield+.

TransFerm Yield+ is a bioengineered drop-in substitute for conventional fermenting yeast that lowers costs and improves efficiencies for corn ethanol producers by:

Concert Pharmaceuticals Initiates Phase 1 Clinical Trial of CTP-354, a Potential Treatment for Spasticity and Pain

Concert Pharmaceuticals Initiates Phase 1 Clinical Trial of CTP-354, a Potential Treatment for Spasticity and Pain

June 10, 2013

LEXINGTON, Mass.--(BUSINESS WIRE)--

T2 Biosystems Appoints Marc Jones and Frédéric Sweeney, Ph.D., to Senior Management Team

T2 Biosystems Appoints Marc Jones and Frédéric Sweeney, Ph.D., to Senior Management Team

June 6, 2013

--Marc Jones to Serve as Chief Financial Officer and Frédéric Sweeney as Senior Director, Business Development--

Receptos Provides Update on Progress of Lead Product Candidate RPC1063

Receptos Provides Update on Progress of Lead Product Candidate RPC1063

June 5, 2013
  • Successfully Completes Thorough QT Study
  • Obtains Special Protocol Assessments (SPAs) From FDA for Phase 3 Trials in Relapsing Multiple Sclerosis

Acceleron Named to the "Best Places to Work" List by The Scientist Magazine

Acceleron Named to the "Best Places to Work" List by The Scientist Magazine

June 4, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Eleven Biotherapeutics Announces Collaboration with ThromboGenics to Develop a Novel Protein Therapeutic for Ophthalmic Disease

Eleven Biotherapeutics Announces Collaboration with ThromboGenics to Develop a Novel Protein Therapeutic for Ophthalmic Disease

May 28, 2013

Eleven's Protein Therapeutic Design Capabilities Combine with ThromboGenics Novel Biologic Target to Treat Back of Eye Diseases

BG Medicine Announces Late-Breaker Oral Presentation of New Data on the BGM Galectin-3(R) Test in Heart Failure

BG Medicine Announces Late-Breaker Oral Presentation of New Data on the BGM Galectin-3(R) Test in Heart Failure

May 28, 2013

European Society of Cardiology Heart Failure Congress Features 15 Presentations and Two Symposia on Galectin-3